Part Five About Supplementary Test Data
Ⅰ、The review criteria for supplementary experimental data in the past two years
There have been positive changes in the review criteria for supplementary experimental data in 2020:
On January 15, 2020, Article 1.10 of the “China-US Economic and Trade Agreement” officially signed by the US and China on drug-related intellectual property rights mentioned the supplementary data rule and mentioned that “China should allow drug patent applicants to use supplementary data in examination procedures, patent reexamination procedures, and judicial procedures to meet relevant requirements for patentability, including requirements for sufficient disclosure and inventiveness.”
Continue Reading Changes and Trends of Compound Patent Invalidation Examination (II)
